Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens

The purpose of this study is to evaluate the safety (adverse events) and performance (visual acuity, spectacle independence) of the SBL-3 intraocular lens.

Inclusion criteria

• ≥ 22 years of age, of any race and either gender
• Operable, age related cataract grade in both eyes
• Patients who require an intraocular lens (IOL) power in the range of 15 D - 30 D only
• Able to comprehend and sign a statement of informed consent
• Calculated lens power within the available supply range
• Planned cataract removal by phacoemulsification
• Potential postoperative visual acuity of 0.2 Logarithm of the Minimum Angle of Resolution (logMAR) or better in both eyes
• In good general and ocular health
• Patients with preoperative astigmatism ≤1.0 D Note: Corneal incisions made to reduce astigmatism will not be allowed during the course of the study.
• Clear intraocular media other than cataract in study eyes
• Preoperative Best Corrected Distance Visual Acuity (BCDVA) worse than 0.2 logMAR
• The subject must be able to undergo second eye surgery between 7 days and 30 days of the first eye surgery
• Able to competently complete testing
• Willing and able to attend study visits

Exclusion criteria

• Previous intraocular surgery
• Preoperative photopic pupil size of < 2.75 mm
• Previous corneal refractive surgery
• Any inflammation or edema (swelling) of the cornea
• Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders ) that are predicted to cause future acuity losses to a level worse than 0.2 logMAR
• Subjects who may reasonably be expected to require a secondary surgical intervention at any time during the study (other than neodymium-doped yttrium aluminium garnet (nd:YAG) capsulotomy)
• Amblyopia
• Clinically significant ptosis
• Clinically severe corneal dystrophy (eg., epithelial, stromal, or endothelial dystrophy), keratitis, keratoconjunctivitis, keratouveitis, keratopathy, or kerectasia
• Diabetic Retinopathy
• Extremely shallow anterior chamber, not due to swollen cataract
• Microphthalmia
• Previous retinal detachment
• Previous corneal transplant
• Severe dry eye
• Recurrent severe anterior or posterior segment inflammation of unknown etiology
• Systemic medications that may confound the outcome or increase the risk to the subject in the opinion of the Investigator [tamsulosin hydrochloride (Flomax) or other medications with similar side effects (floppy iris syndrome)]
• Rubella or traumatic cataract
• Iris neovascularization
• Glaucoma (medically controlled or uncontrolled)
• Aniridia
• Chronic severe uveitis
• Optic nerve atrophy
• Corneal decompensation
• Greater than 1.0 D of astigmatism
• History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.)
• Pseudoexfoliation syndrome
• Iris atrophy
• Pupil abnormalities (e.g., corectopia)
• Aniseikonia
• An acute or chronic disease or illness that may confound the results of this investigation (e.g., immunocompromised, connective tissue disease, clinically significant atopic disease, diabetes, and any other such disease or illness)
• Pregnant, lactating, or planning to become pregnant during the course of the trial Note: Subjects who become pregnant during the study will not be discontinued; however, data may be excluded from the effectiveness analyses because pregnancy can alter refraction and visual acuity results.
• Participation in another clinical trial within 30 days of study start